

Special Issue

Antibiotics and Infectious Respiratory Diseases

Message from the Guest Editors

Infectious respiratory diseases (IRD) remain among the most important causes of morbidity and mortality worldwide and, in the era of the COVID-19 pandemic, they have come into major focus in the scientific world and the global health approach. They can have a viral, bacterial, parasitic, and opportunistic origin. Effective management of respiratory infectious diseases to reduce their burden and to avoid overuse of antibiotics has become a great therapeutic and public health challenge. Manuscripts covering all aspects of research relating to IRD prevention, diagnosis, management, and treatment are welcome. In addition, manuscripts covering these areas of interest are welcome:

- Bacterial host resistance and antimicrobial resistance;
- HAP (hospital-acquired pneumonia), VAP (ventilator-associated pneumonia), CAP (community-acquired pneumonia);
- Tuberculosis and nontuberculous mycobacteria (NTM);
- Viral pneumonia and SARS CoV2 interstitial pneumonia;
- Educational on antimicrobial resistance and antimicrobial prescription;
- Pneumonia infection in immunocompetent and immunosuppressed patients.

Guest Editors

Dr. Francesco Di Gennaro

Dr. Gina Gualano

Dr. Fabrizio Palmieri

Deadline for manuscript submissions

closed (15 March 2022)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/77639

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)